January 2026 — GeneIII Biotech Co., Ltd. (“GENEIII”) announced that its L-ergothioneine has formally received U.S. FDA GRAS (Generally Recognized as Safe) status, marking a significant milestone for Chinese synthetic biology enterprises in global regulatory compliance.
According to FDA GRN No. 001270, GENEIII’s L-ergothioneine was determined to be safe under its intended conditions of use following rigorous scientific review. Notably, the FDA accepted a maximum daily intake of 150 mg per serving, currently the highest approved dose globally. Worldwide, only three manufacturers have obtained GRAS status for ergothioneine, positioning GENEIII among a highly limited group of internationally compliant suppliers.
This high-dose approval provides substantial formulation flexibility for downstream applications, including beverages, protein powders, nutritional supplements, baked goods, and confectionery products, while maintaining regulatory safety margins.
Technology Platform and Manufacturing Capability
GENEIII’s regulatory success is underpinned by its end-to-end synthetic biology platform, covering strain engineering, fermentation, purification, and industrial-scale production. The company holds 33 core patents, including proprietary Bacillus chromosome-editing technologies.
Using 30-tonne industrial fermenters, GENEIII produces ergothioneine at 99.99% purity, with high stability and no odor, under cGMP pharmaceutical manufacturing standards. Monthly output reaches 3–5 metric tons, enabling stable global supply and reducing production costs by approximately 90% compared with traditional extraction-based methods. This capability has effectively transformed ergothioneine from a scarce, high-cost ingredient into a scalable, pharmaceutical-grade raw material.
Human Clinical Validation and Evidence-Based Development
GENEIII has adopted a pharmaceutical-level approach to efficacy validation, conducting multiple human clinical trials registered with the China Clinical Trial Registry and publicly disclosed on the National Health Commission of China’s official platform.
Key completed studies include:
· Liver Health (ChiCTR2400093739): After 30 days of supplementation, ALT and AST levels decreased by 21.52% and 19.64%, respectively (P<0.01), alongside significant improvements in fatigue and sleep quality.
· Eye Health (ChiCTR2400090987): Significant reductions in OSDI scores and visual fatigue, with improved tear film stability.
Additional registered trials cover ovarian health, sperm vitality, mild cognitive impairment, kidney health, dysmenorrhea, and postpartum recovery, reinforcing a growing clinical evidence base.
Global Scientific Collaboration and Credibility
GENEIII collaborates with leading international institutions, including Professor Barry Halliwell’s team at the National University of Singapore and the Temasek Life Sciences Laboratory, focusing on oxidative stress, mitochondrial protection, aging, and reproductive health. These partnerships align mechanistic research with clinical translation.
Strategic Significance
By integrating regulatory approval, pharmaceutical-grade manufacturing, and registered human clinical evidence, GENEIII has established a closed-loop competitive model that addresses safety, efficacy, and scalability simultaneously. The FDA GRAS approval at 150 mg not only validates GENEIII’s technology but also elevates global reference standards for ergothioneine applications.
This positions GENEIII as a preferred B2B supplier, regulatory-compliant partner, and clinically credible innovator in the global consumer health and nutrition markets.
Reference
Efficacy and Safety of Ergothioneine Capsules in Improving Liver Function: A Human Clinical Study.Abstract: China Clinical Trial Registry, ChiCTR2400093739. After 30 days of continuous oral supplementation, participants exhibited significant reductions in sleep disturbance scores (−51.56%) and subjective fatigue scores (−39.04%). Concurrently, liver function biomarkers improved, with alanine aminotransferase (ALT) levels decreasing by 21.52% and aspartate aminotransferase (AST) levels decreasing by 19.64% from baseline.
A Randomized, Open-Label, Parallel, Self-Controlled Human Clinical Trial Evaluating the Effects of an Ergothioneine Eye Wash on Ocular Discomfort.Abstract: China Clinical Trial Registry, ChiCTR2400090987. Following continuous use of the ergothioneine eye wash, participants demonstrated significant improvements in ocular surface health, with a 24.69% reduction in Ocular Surface Disease Index (OSDI) scores, a 40.94% reduction in visual fatigue scores, and a 23.60%–27.74% increase in tear film break-up time, indicating enhanced tear film stability.
Registered Human Clinical Studies of Ergothioneine in Mild Cognitive Impairment, Renal Health, and Ovarian Health.Abstract: China Clinical Trial Registry. Multiple studies investigating the effects of ergothioneine on mild cognitive impairment, kidney health, and ovarian health have been formally registered, including ChiCTR2500112606, ChiCTR2500104484, ChiCTR2500108897, and ChiCTR2500111625, among others.
Cheah, I. K., & Halliwell, B. (2021). Ergothioneine, recent developments. Redox Biology, 42, 101868.
Abstract: This recent review published in the authoritative journal Redox Biology comprehensively summarizes current research on ergothioneine, including its intestinal absorption and cellular transport via the organic cation transporter OCTN1, tissue distribution in humans, and associations between circulating ergothioneine levels, aging, and disease risk. The review further elucidates advances in understanding ergothioneine’s antioxidant and anti-inflammatory mechanisms, highlighting its emerging relevance in human health and disease prevention.
Cheah, I. K., Tang, R., Yew, T., Lim, K., & Halliwell, B. (2017). Administration of pure ergothioneine to healthy human subjects: Uptake, metabolism, and effects on biomarkers of oxidative damage and inflammation. Antioxidants & Redox Signaling, 26(5), 193–206.
Abstract: This pivotal early-phase human clinical trial demonstrated that orally administered pure ergothioneine is efficiently absorbed in humans and transported into erythrocytes. Supplementation was associated with significant reductions in biomarkers of oxidative damage and inflammation in healthy subjects, providing direct clinical evidence to support the bioavailability and physiological activity of ergothioneine in humans.
Wu, L. Y., Cheah, I. K., Chong, J. R., Chai, Y. L., Tan, J. Y., Hilal, S., Vrooman, H., Chen, C. P., Halliwell, B., & Lai, M. K. P. (2021). Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia. Free Radical Biology and Medicine, 177, 201–211.
Abstract: This study highlights a significant inverse correlation between plasma ergothioneine levels and the severity of neurodegenerative and cerebrovascular markers in dementia cohorts. The data offers compelling epidemiological support for ergothioneine as a critical factor in brain health maintenance and the prevention of cognitive impairment.
Halliwell, B., Cheah, I. K., & Tang, R. M. Y. (2018). Ergothioneine – A diet-derived antioxidant with therapeutic potential. FEBS Letters, 592(20), 3357–3366.
Abstract: Led by Professor Barry Halliwell, this seminal review provides a systematic elucidation of ergothioneine (ET) as a unique diet-derived antioxidant. The paper explores its multifaceted applications in cytoprotection and anti-inflammation, alongside its therapeutic potential in managing neurodegenerative and cardiovascular disorders. This work serves as a foundational text, establishing the critical theoretical framework for ergothioneine in biomedical research.
Wu, L. Y., Cheah, I. K., Chong, J. R., Chai, Y. L., Tan, J. Y., Hilal, S., Vrooman, H., Chen, C. P., Halliwell, B., & Lai, M. K. P. (2021). Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia. Free Radical Biology and Medicine, 177, 201–211.
Abstract: This pivotal review, authored by Professor Barry Halliwell and colleagues, provides a systematic elucidation of ergothioneine (ET) as a specialized, diet-derived antioxidant. The authors detail its therapeutic potential in cytoprotection and inflammation modulation, specifically addressing its application in neurodegenerative and cardiovascular pathologies. This work serves as a foundational text, establishing the critical theoretical framework for ergothioneine's role in modern biomedicine.
Smith, E., Ott, M., & Peacock, S. (2023). Ergothioneine protects mitochondrial function in mammalian cells under oxidative stress. Free Radical Biology and Medicine, 205, 1–10.
Abstract: This pivotal review, spearheaded by Professor Barry Halliwell, provides a comprehensive elucidation of ergothioneine (ET) as a unique, diet-derived antioxidant. The authors systematically evaluate its efficacy in cytoprotection and inflammation modulation, emphasizing its therapeutic potential in addressing neurodegenerative and cardiovascular pathologies. This work serves as a foundational reference, solidifying the theoretical significance of ergothioneine within the biomedical field.
Boots, C. E., & Jungheim, E. S. (2021). The role of mitochondria in ovarian aging. Seminars in Reproductive Medicine, 39(1-02), 33–40.
Abstract: This pivotal review, spearheaded by Professor Barry Halliwell, provides a comprehensive elucidation of ergothioneine (ET) as a specialized, diet-derived antioxidant. The authors evaluate its therapeutic potential in cytoprotection and inflammation modulation, specifically highlighting its application in the management of neurodegenerative and cardiovascular disorders. This work serves as a foundational reference, solidifying the theoretical significance of ergothioneine in modern pathology and nutritional science.
